Technology
Health
Medical

Sientra

$9.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (0.82%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Sientra and other stocks, options, ETFs, and crypto commission-free!

About

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. Read More The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini in August 29, 2003 and is headquartered in Santa Barbara, CA.

Employees
259
Headquarters
Santa Barbara, California
Founded
2003
Market Cap
279.42M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
516.31K
High Today
$10.03
Low Today
$9.27
Open Price
$9.70
Volume
409.87K
52 Week High
$26.79
52 Week Low
$7.75

Collections

Technology
Health
Medical
2014 IPO
US
North America

News

Seeking AlphaMar 20

Sientra responds to FDA warning letter; shares down 2% after hours

In a statement, breast implant maker Sientra (NASDAQ:SIEN) says it will take "all necessary steps" to address the FDA warning letter it received this week, adding that the totality of the clinical and real-world data confirms the long-term safety and effectiveness of its products.

244
ReutersMar 19

J&J and Sientra get FDA warning letters over breast implants

(Reuters) - The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.

272
New York TimesMar 19

Reports of Breast Implant Illnesses Prompt Federal Review

After having the implants removed in 2015, she said, her health has improved. Though she still has some bad days, Ms. Cook said, β€œIt’s been like a 180.” Silicone-filled breast implants were first marketed in the United States in the 1960s. Over the next few decades, reports of illness emerged. In 1992, silicone implants were banned, except for reconstruction after mastectomy or to replace a previous implant, and then only in clinical trials. A flood of lawsuits followed. Studies conducted afterward gener...

112

Earnings

-$0.99
-$0.84
-$0.69
-$0.54
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.68 per share
Actual
-$0.86 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.